Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department

Rudnitsky, Gail; Eberlein, R.; Schoffstall, John M.; Mazur, Janice E; Spivey, William H

doi:10.1016/s0196-0644(05)80411-1

Cited by 87 publications

(36 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Rapid-acting inhaled b 2 -agonists should be administered at regular intervals (Evidence A) [337][338][339]. Although most rapid-acting b 2 -agonists have a short duration of effect, the long-acting bronchodilator formoterol, which has both a rapid onset of action and a long duration of effect, has been shown to be equally effective without increasing side-effects, though it is considerably more expensive [285].…”

Section: Treatmentmentioning

confidence: 99%

Global strategy for asthma management and prevention: GINA executive summary

Bateman

Ss²,

Barnes³

et al. 2007

Eur Respir J

2,666

2,301

View full text Add to dashboard Cite

Asthma is a serious health problem throughout the world. During the past two decades, many scientific advances have improved our understanding of asthma and ability to manage and control it effectively. However, recommendations for asthma care need to be adapted to local conditions, resources and services. Since it was formed in 1993, the Global Initiative for Asthma, a network of individuals, organisations and public health officials, has played a leading role in disseminating information about the care of patients with asthma based on a process of continuous review of published scientific investigations. A comprehensive workshop report entitled ''A Global Strategy for Asthma Management and Prevention'', first published in 1995, has been widely adopted, translated and reproduced, and forms the basis for many national guidelines. The 2006 report contains important new themes. First, it asserts that ''it is reasonable to expect that in most patients with asthma, control of the disease can and should be achieved and maintained,'' and recommends a change in approach to asthma management, with asthma control, rather than asthma severity, being the focus of treatment decisions. The importance of the patient-care giver partnership and guided self-management, along with setting goals for treatment, are also emphasised.

show abstract

Section: Treatmentmentioning

confidence: 99%

Global strategy for asthma management and prevention: GINA executive summary

Bateman

Ss²,

Barnes³

et al. 2007

Eur Respir J

2,666

2,301

View full text Add to dashboard Cite

show abstract

“…salbutamol and fenoterol, are the cornerstone of bronchodilator treatment for acute asthma exacerbations [1,11,12] (evidence A). They act by stimulating β 2 receptors in the airways.…”

Section: β 2 -Agonistsmentioning

confidence: 99%

“…[15] How to administer? SABAs are administered repeatedly as the best way of achieving rapid reversal of airflow obstruction (Table 4) [11,12] (evidence A). If the attack is severe or life-threatening, delivery via an oxygendriven nebuliser is mandatory.…”

Section: β 2 -Agonistsmentioning

confidence: 99%

Guideline for the management of acute asthma in adults: 2013 update

et al. 2012

View full text Add to dashboard Cite

“…Because the administered dose depends on the patient's lung volume and inspiratory flow rates, the same dose can be used in most patients regardless of age or size. Although 6 adult studies 5 and 1 pediatric study 6 showed no difference in the effects of continuous versus intermittent administration of nebulized albuterol, continuous administration was more effective in the subset of patients with severe exacerbations of asthma, 7,8 and it was more cost-effective in a pediatric trial. 6 A Cochrane meta-analysis showed no overall difference between the effects of albuterol delivered by metered dose inhaler (MDI)-spacer or nebulizer, 9 but MDI-spacer administration can be difficult in patients in severe distress.…”

Section: Primary Therapymentioning

confidence: 96%

Part 10.5: Near-Fatal Asthma

Wilkins¹

2005

Circulation

View full text Add to dashboard Cite

A sthma accounts for Ͼ2 million emergency department visits and 5000 to 6000 deaths annually in the United States, many occurring in the prehospital setting. 1 Severe asthma accounts for approximately 2% to 20% of admissions to intensive care units, with up to one third of these patients requiring intubation and mechanical ventilation. 2 This section focuses on the evaluation and treatment of patients with near-fatal asthma. PathophysiologyThe pathophysiology of asthma consists of 3 key abnormalities:Complications of severe asthma, such as tension pneumothorax, lobar atelectasis, pneumonia, and pulmonary edema, can contribute to fatalities. Cardiac causes of death are less common.

show abstract

Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department

Cited by 87 publications

References 3 publications

Global strategy for asthma management and prevention: GINA executive summary

Global strategy for asthma management and prevention: GINA executive summary

Guideline for the management of acute asthma in adults: 2013 update

Part 10.5: Near-Fatal Asthma

Contact Info

Product

Resources

About